Journal article

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W Roberts, Andrew H Wei, David CS Huang

BLOOD | AMER SOC HEMATOLOGY | Published : 2021

Abstract

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in hematologic cancers and play important roles in their biology either through dysregulation or by virtue of intrinsic importance to the cell-of-origin of the malignancy. A new class of small-molecule anticancer drugs, BH3 mimetics, now enable specific targeting of these proteins in patients. BH3 mimetics act by inhibiting the prosurvival BCL2 proteins to enable the activation of BAX and BAK, apoptosis effectors that permeabilize the outer mitochondrial membrane, triggering apoptosis directly in many cells and sensitizing others to cell death when combined with other antineoplastic drugs. Venetoclax, a specific inhibi..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

Academic research in the A.W.R., A.H.W., and D.C.S.H. laboratories has been supported over the last 20 years by grants from the National Health and Medical Research Council of Australia, the Leukemia and Lymphoma Society, Cancer Council of Victoria, Victorian Cancer Agency, Australian Cancer Research Foundation, Leukaemia Foundation of Australia, the Snowdome Foundation, and the Medical Research Future Fund.